

JULY 6, 1988

St. Vincent Medical Center

UNITED STATES NUCLEAR REGULATORY COMMISSION REGION III 799 ROOSEVELT ROAD GLEN ELLYN, ILLINDIS 60137

ATTN: CASSANDRA FRAZIER MATERIALS LICENSING SECTION

RE: BYPRODUCT MATERIALS LICENSE NO. 34-01216-03 CONTROL NO. 85303 ST. VINCENT MEDICAL CENTER 2213 CHERRY STREET TOLEDO, OHIO 43608

DEAR MS. FRAZIER:

WITH RESPECT TO AMENDMENT NO. 43 OF THE ABOVE-NOTED BYPRODUCT MATERIALS LICENSE AND YOUR LETTER OF MAY 6, 1988, PLEASE NOTE THE FOLLOWING:

1. ATTACHED FLEASE FIND A LETTER FROM THE CHAIRMAN OF THE RADIATION SAFETY COMMITTEE OF THE MEDICAL COLLEGE OF OHIO. LICENSE NO. 34-13011-04 STATING THEIR AUTHORIZATION FOR ROGER AHUJA, M.D. DR. AHUJA REQUESTED AUTHORIZED USER STATUS FOR MATERIALS IN 10.CFR.35.400 AND 10.CFR.35.600.

2. ATTACHED PLEASE FIND AN ADDITIONAL SUPPLEMENT B FOR SHEILA S. MANION, M.D., DOCUMENTING HER TRAINING AND EXPERIENCE IN THE USE OF IODINE-131 FOR HYPERTHYROIDISM, CARDIAC DYSFUNCTION, AND THRYOID CARCINOMA.

3. PLEASE CHANGE ITEM 12H. IN AMENDMENT 43 TO AUTHORIZE M.F. FADELL, M.D. FOR MATERIAL IN 100FR 35.100 AS WELL AS 35,200 (LISTED TWICE), 35.300, AND 35.500.

AS PER YOUR RECOMMENDATION, I HAVE REFERENCED CONTROL NO. 85303, SINCE THIS INFORMATION REPRESENTS CLARIFICATION OF REQUESTS SUBMITTED FOR AMENDMENT NO. 43. ACCORDINGLY, NO FEE IS ATTACHED TO THIS REQUEST.

THANK YOU IN ADVANCE FOR YOUR ATTENTION TO THES

CONTROL NO. 8582 1

SINCERELY. awance

905080414 880815 EG3 LIC30 4-01216-03 PMI

Sam and

CAWRENCE D. LEAMAN PRESIDENT ST. VINCENT MEDICAL CENTER

2213 Cherry Street, Toledo, Ohio 43608-2691 419/321-3232


RECEIV

JUL 29 1988 JUL 29 1988

Medical College of Ohio

419-381-4172

3000 Arlington Avenue Mailing Address: C.S. 10008 Toledo, Ohio 43699



419-381-3426



Medical Physics 419-381-4301

July 7, 1988

Kathryn J. Williford, Ph.D. St. Vincent Medical Center 2213 Cherry Street Toledo, OH 43608

Dear Dr. Williford:

In response to your request, I am providing information regarding the activities of Rajender K. Ahuja, M.D. while he was a member of our medical staff. He participated in clinical radiation oncology during the period from June 1982 to December 1986 under our NRC License No. 34-13011-04.

Dr. Ahuja was approved by the Radiation Safety and Radioisotope Committee for the following:

- 1) Use of Byproduct Material Listed in Group VI of 10 CFR 35.100 (Equivalent to current §35.400 sources for brachytherapy)
- 2) Use of iodine-131 as iodide for treatment of thyroid carcinoma
- 3) Use of phosphorus-32 for intracavitary treatment

In support of his application for use of the above materials, he provided evidence of experience and certification by the American Board of Radiation Oncology, June 1982.

Please feel free to contact me if further information is required.

Sincerely,

William J. Potvin, Ph.D., Chairman Radiation Safety & Radioisotope Committee

WJP/ps



a

NAC FORM 313M SUPPLEMENT B

U. S. NUCLEAR REGULATORY COMMISSION

1

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS		KEY TO COLUMN C		
			PERSONAL PARTICIPATION SHOULD CONSIST OF:	
Sheila S. Manion, M.D.			 Supervised examination of patients to determine the suitability for radioisotops diagnosis and/or treatment and recommendation for prescribed dosage. 	
STREET	ADDRESS		2-Collabor	ation in dose calibration and actual administration of dose
1288	East Meadow		to the pa	itient including calculation of the radiation dose, related ments and plotting of data,
CITY	STATE ZIPC	ODE	3-Adequat	e period of training to enable physician to manage radioactive
Orego	n, Ohio 43616		treatmen	and follow patients through diagnosis and/or course of ht.
01080	2. CLINICAL TRAINING AND	EXPERI	ENCE OF	ABOVE NAMED PHYSICIAN
	T CENTRAL MAILING AND		BEROF	Above nameb rintsician
ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	CASES INVOLVING PERSONAL PARTICIPATION		(Additional information or comments may
A	В	C		be submitted in duplicate on separate sheets.) D
	DIAGNOSIS OF THYROID FUNCTION			
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME			
1-131 or 1-125	LIVER FUNCTION STUDIES			
	FAT ABSORPTION STUDIES			
	KIDNEY FUNCTION STUDIES	e e a tord la construction	10-10-10-10-10-10-10-10-10-10-10-10-10-1	
	IN VITRO STUDIES		988-107-001013-155 year-ont-proci yea	
OTHER				
1.125	DETECTION OF THROMBOSIS			
1-131	THYROID IMAGING			
P-32	EYE TUMOR LOCALIZATION	- Al an	2	
Se- 75	PANCREAS IMAGING			
Yb-169	CISTERNOGRAPHY			
Xe-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES			
OTHER				· · · · · · · · · · · · · · · · · · ·
	BRAIN IMAGING			
	CARDIAC IMAGING			
	THYROID IMAGING			
	SALIVARY GLAND IMAGING			
Tc-99m	BLOOD POOL IMAGING			
	PLACENTA LOCALIZATION			
	LIVER AND SPLEEN IMAGING			
	LUNG IMAGING			
	BONE IMAGING			
OTHER				

Page 6 CONTROL NO 8582 1

and b	PRECEP	R STATEMENT	(Continued)
	2. CLINICAL TRAINING AND EX	PERIENCE OF ABO	VE NAMED PHYSICIAN (Continued)
ISOTOPE	CONDITIONS DIAGNOSED OR TREATED	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets,)
A	В	с	D
P-32 (Soluble)	TREATMENT OF POLYCYTHEMIA VERA, LEUKEMIA, AND BONE METASTASES		
P-32 (Colloidal)	INTRACAVITARY TREATMENT		
1.131	TREATMENT OF THYROID CARCINOMA	3	
	TREATMENT OF HYPERTHYROIDISM	8	
Au-198	INTRACAVITARY TREATMENT		
Co-60	INTERSTITIAL TREATMENT		
or Cs-137	INTRACAVITARY TREATMENT		
1-125 or 1r-192	INTERSTITIAL TREATMENT		
Co-60 Or Cs-137	TELETHERAPY TREATMENT		
Sr-90	TREATMENT OF EYE DISEASE		
and the families of the second second second	RADIOPHARMACEUTICAL PREPARATION		
Mo-99/ Tc-99m	GENERATOR		
Sn-113/ In-113m	GENERATOR		
Tc-99m	REAGENT KITS	and the set of the set	
	AND TOTAL NUMBER OF HOURS RECE		
. THE TR	AINING AND EXPERIENCE INDICATED	ABOVE 5. PRECES	TOR'S SIGNATURE
	OF SUPERVISOR	_ >	N. (Finel
	T. Pinsky, M.D.	0	
	. Vincent Medical Center	7. PRECEP	TOR'S NAME (Please type or print)
c. MAIL	ING ADDRESS		F Dipoky M D
d. CITY	13 Cherry Street	8. DATE	Γ. Pinsky, M.D.
	ledo, Ohio 43608		July 6, 1988
. MATERI 34-0121	ALS LICENSE NUMBER(S) 6-03		July 0, 1900 .
C EODM	313M SUPPLEMENT B		